ClinicalTrials.gg
CompletedNCT05752461Updated Jan 20, 2025

SHR-2004 for the Prevention of Venous Thromboembolism in Patients Undergoing Total Knee Arthroplasty

A Phase 2 interventional study of SHR-2004 injection and SHR-2004 injection in Prevention of Venous Thromboembolism After Knee Arthroplasty, sponsored by Beijing Suncadia Pharmaceuticals Co., Ltd. Completed at 1 site in China. Open to participants aged 40 Years to 80 Years. Per ClinicalTrials.gov, last updated 2025-01-20.

Sponsored by Beijing Suncadia Pharmaceuticals Co., Ltd (part of Jiangsu HengRui Medicine Co., Ltd.) · Phase 2, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
353
Allocation
Randomized
Ages
40 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 62 studies in Venous Thromboembolism with a site in China — 21 open to participants now, 23 under way, 2 of them phase 3. Venous Thromboembolism · China.

Enrollment
23rd of 33
353 · median 530
Started
2023
with 5 others
Phase 2
2 of 62
none open now
Registered
38th of 62
by date
Lead sponsor
2 of 62
Beijing Suncadia Pharmaceuticals Co., Ltd

Among the 62 studies in Venous Thromboembolism with a site in China, this one is the 23rd largest by enrollment of the 33 interventional ones that give a count, is one of 6 that started in 2023, is one of 2 in phase 2, and was the 38th registered.

Venous Thromboembolism

713 studies on the registry are indexed under Venous Thromboembolism; 147 are open to participants now.

Browse Venous Thromboembolism studies →

Open to participants now

21 of the 62 studies in Venous Thromboembolism with a site in China are open now. Recruiting first, the newest first:

16 more — sign in →

All 21 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 113 Venous Thromboembolism studies recruiting now, 90 (80%) set no upper age limit and 13 (12%) stop at 75 or younger; 9 take children under 18; 10 take healthy volunteers.

This study: 40 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 62 studies in Venous Thromboembolism with a site in China, or all of them as a file.
02

Study summary

The purpose of the study is to evaluate the efficacy and safety of SHR-2004 in preventing venous thromboembolism after elective unilateral total knee arthroplasty

03

Conditions studied

  • Prevention of Venous Thromboembolism After Knee Arthroplasty
04

Who can participate

Ages eligible
40 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Understand the research procedures and methods, volunteer to participate in the study, and sign the
  2. Scheduled to undergo elective unilateral total knee arthroplayts (TKA)
  3. Male or female(≥ 40 years old and \< 80 years old)

Exclusion criteria

Exclusion Criteria:

  1. Unable to receive CT angiography of both lower limbs;
  2. Malignant tumor within one year of the screening ;
  3. History of venous thromboembolism;
  4. Myocardial infarction, or ischemic stroke occurred within 6 months of the screening;
  5. Any medical history that may increase the risk of bleeding or any conditions that the investigator considers to increase the risk of bleeding
  6. Any of the laboratory test indicators meets the following criteria:

    ①estimated \< 60 mL/min/1.73m2 ;

    ② (ALT) or aspartate aminotransferase (AST) >3 times the value (ULN);

    ③total was > 2 times, etc

  7. History of drug abuse;
  8. Pregnant or lactating women
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

05

Study design

Phase
Phase 2
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
353 participants (actual)

Study arms

  • Experimental
    Treatment group A: SHR-2004 injection

    Drug: SHR-2004 injection

  • Experimental
    Treatment group B: SHR-2004 injection

    Drug: SHR-2004 injection

  • Experimental
    Treatment group C: SHR-2004 injection

    Drug: SHR-2004 injection

  • Active comparator
    Treatment group D: Enoxaparin sodium injection

    Drug: Enoxaparin sodium injection

Interventions

06

What researchers measure

Primary outcomes

  1. Incidence of composite endpoint consisting of asymptomatic DVT as detected by mandatory bilateral CT venography, confirmed symptomatic DVT, non-fatal PE and all-cause death(Primary efficacy outcome)

    Time frame: Day 12

  2. Incidence of composite endpoint of major and clinically relevant non-major bleeding(Primary safety outcome)

    Time frame: Day 12

Secondary outcomes

  1. Incidence of composite endpoint consisting of asymptomatic DVT as detected by mandatory bilateral CT venography, confirmed symptomatic DVT, non-fatal PE and all-cause death(Secondary efficacy endpoint)

    Time frame: Day 85

  2. Incidence of composite endpoint of any bleeding(Secondary safety endpoint)

    Time frame: Day 12

  3. Incidence of composite endpoint of major and clinically relevant non-major bleeding(Secondary safety endpoint)

    Time frame: Day 85

07

Study locations

1 site
  • Xiangya Hospital Central South University
    Changsha, Hunan 410008, China
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2023 to primary completion in Apr 2024, 12 months.

Of 27 phase 2 interventional studies under Venous Thromboembolism, half reached primary completion within 26 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 50. This study's 12 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 22, 2023
First posted
Mar 2, 2023
StartActual
Apr 12, 2023
Primary completionActual
Apr 12, 2024
CompletionActual
Jun 25, 2024
Last update
Jan 20, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 20, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05752461
Responsible party
Sponsor
First posted
Mar 2, 2023
Start date
Apr 12, 2023
Primary completion
Apr 12, 2024
Completion
Jun 25, 2024
Last update
Jan 20, 2025

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: SHR-2004

Start the discussion